Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated Disease

(MedPage Today) — Adding ivonescimab to chemotherapy prolonged progression-free survival (PFS) in previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC), but failed to significantly improve overall survival (OS), the phase…